Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...
A shift toward personalized treatments and programmable cell therapies opens new doors for scientists engineering T cell-based treatments.
Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...
Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.
CAR T-cell therapy for lupus is still in Phase 1 trials but if all continues to go well, Desai said it could be about five to ...
In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete ...
While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...
Northwestern Medicine scientists in the laboratory of Stephen Miller, Ph.D., professor emeritus of Microbiology–Immunology, have identified the cellular and molecular mechanisms required for the ...
For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell-known as helper T cells-from stem cells in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results